AI-generated clinical documents promise faster turnaround, from protocols drafted in hours to Clinical Study Reports derived from structured outputs. But speed alone doesn't equal regulatory readiness. The critical question for sites and sponsors is how AI systems interact with CDISC standards, and whether those systems treat CDISC requirements as hard constraints or flexible suggestions.
CDISC standards (CDASH, SDTM, ADaM, SEND) are mandatory for FDA submissions under specific timelines. AI tools must respect CDISC Controlled Terminology, which governs coded values in datasets. An AI that generates non-standard race categories or lab test names creates traceability gaps that surface during regulatory review.
AI has shown genuine value in SDTM mapping, where machine learning reduces manual programming while maintaining conformance. A 2024 peer-reviewed study and industry case studies demonstrate that AI-generated mappings work when human review validates each output before submission.
The shift to structured protocols under ICH M11 and CDISC's Unified Study Definition Model changes the game. When protocols exist as machine-readable USDM data rather than narrative PDFs, AI can ingest design elements with far greater accuracy, reducing transcription errors in downstream documents like informed consents.